Slash a mouse’s food intake by 40% and it might survive longer. It will also become worse at fighting off infections, reproduce less successfully, and grow poorly. Aging researchers have wrestled with that trade-off for decades, and it explains why no credible scientist has ever advised starving your way to your 90s.
New research in Nature Aging hints at a detour around the problem. The focus: an immune protein known as complement component 3, or C3.
The trial that makes this worth taking seriously
Fruit flies, rhesus monkeys, and mice supply most of what we know about calorie restriction. Evidence from people is scarce, which is precisely why the CALERIE trial carries weight here. Backed by funding from the National Institutes of Health, the two-year study had participants trim their calorie intake by 11 to 14% without leaving them feeling deprived.
"It’s the only trial of its kind that has been done with such rigor and control and demonstrates relevance to human physiology," said Vishwa Deep Dixit, PhD, Waldemar Von Zedtwitz Professor of Pathology, professor of immunobiology and of comparative medicine, and director of the Yale Center for Research on Aging (Y-Age) at Yale School of Medicine.
Earlier work from Dixit’s lab had already established that a 14% calorie cut sustained over two years strengthened people’s immune defenses, with none of the growth or reproductive damage that undermines the mouse experiments. What fails at severe levels appears to work at moderate ones.
"This concept demonstrates that aging is actually malleable and a process that can be targeted," Dixit said.
One protein out of more than 7,000
In the latest study, the researchers analyzed plasma drawn from 42 CALERIE participants, profiling upwards of 7,000 proteins in samples gathered over time. After calorie restriction, C3 levels showed a significant decline.
C3 belongs to the complement system, a protein network that helps the body fend off pathogens. Prior studies had raised the possibility that switching that system on feeds chronic inflammation, widely regarded as a central hallmark of aging and of many age-linked diseases. The missing piece was causation.
"But the causal effects of C3 in aging and chronic inflammation have not been identified. So, we were very excited to find that in our study," said Hee-Hoon Kim, PhD, a postdoctoral associate in the Dixit lab and a co-first author of the paper.
The source was in the wrong organ
Measuring protein levels before and after the two-year regimen singled out white adipose tissue — the principal form of fat tissue in mammals — as the tissue most altered by the dietary change. C3 expression climbed with age in mice, and biochemical assays traced much of that rise to visceral white adipose tissue.
That answer came as a surprise.
"We were not expecting that because these proteins are mainly synthesized in the liver," said Manish Mishra, PhD, a postdoctoral associate in the Dixit lab and a co-first author of the study.
Single-cell RNA sequencing tightened the focus further, landing on age-associated macrophages — white blood cells residing within the fat tissue itself. Best known as first responders that swallow pathogens, macrophages also play a role in keeping tissue functioning normally, Dixit noted.
"This whole process was unknown in the beginning," Mishra said. "Just to narrow it down to the subtypes of macrophages responsible for this complement protein production was very challenging."
Weight loss wasn’t doing the work
One result is what elevates this from intriguing biology to a plausible drug target. Participants shed roughly 18 pounds apiece across the two years, so the intuitive explanation would be simple: less fat, less C3.
Yet when the team plotted shifts in body mass index against shifts in complement protein levels, no correlation emerged between how much weight someone lost and how steeply those proteins fell.
"This suggests that calorie restriction has a beneficial effect that is unique to adipose tissues and is likely independent of weight loss," Kim said.
That prompted a direct test of the shortcut. Giving mice a drug that blocks C3 activation — reproducing a single effect of calorie restriction — left the animals with less age-related inflammation.
A 1952 idea explains why this happens
Dixit interprets the finding through antagonistic pleiotropy, an account of certain aspects of aging put forward by biologist Peter Medawar in 1952. Machinery that serves us well in youth can become a liability down the line.
Growth hormone is the classic illustration: indispensable during early development, yet later in life it may also contribute to cancer.
C3 and related proteins evolved as a defense against infection. Because humans now survive far beyond the lifespans of their ancestors, some of those protective systems may eventually begin driving disease instead. Dialing down excessive C3 activity could potentially help extend health span, Dixit said.
What happens next, and the obvious risk
The group is now investigating whether FDA-approved inhibitor drugs might tamp down C3 production and potentially slow certain aspects of human aging. Repurposing existing approved medicines beats building one from the ground up on speed — but the hazard is baked into the biology: shut down complement and you have shut down part of your defense against infection.
"The idea is not to remove complement systems that are required for us to fight infections," Dixit said. "Instead, the goal is to restore the balance."
Until researchers work out that balance in humans rather than mice, the sole intervention supported by two years of controlled human data remains the CALERIE approach: consuming 11 to 14% fewer calories, without feeling deprived.